|
|
2890 Centre Pointe Drive,St.Paul
Minneapolis, MN 55113 USA
phone:651-757-4300
fax:651-757-3470
|
|
| Symbol |
Private |
| Founded |
2006 |
| Employees |
20 |
|
|
| www.apnexmedical.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Neurostimulation therapy for the treatment of obstructive sleep apnea |
|
| Management |
| Robert Atkinson, President and CEO |
| |
|
|
| |
|
| Keywords |
| Sleep, Neurology, pulmonology, Sleep Apnea, heart failure, narcolepsy, neurostimulation, brain, respiration |
|
|
|
| Description |
|
Apnex Medical is a medical device company developing therapies for obstructive sleep apnea, a disorder that interrupts breathing during sleep. The company's technology is an implantable neurostimulator designed to open the airway muscles that can close during an apnea episode. |
|
| Products / Services |
The Apnex device is similar in design to a cardiac pacemaker, but rather than connecting to the heart, the device attaches to a nerve in a patient's airway.
|
|
| Technology / Differentiation |
| Apnex's sleep apnea device stimulates nerves controlling a patient's airway, keeping it open during sleep and preventing nighttime breathing interruptions responsible for a number of medical ailments. |
|
| Market / Customers |
The market for sleep apnea equipment in the U.S. is currently estimated at $1.3 billion a year. The incidence of sleep apnea continues to rise.
|
|
| Funding |
| May 15, 2007. Apnex-Medical raised $16.1 million in a first round of funding. Participants included Domain Associates, New Enterprise Associates, Polaris Ventures Partners and Apnex Chairman Michael Berman. |
|
| Status |
| Apnex is a development/pre-clinical stage company with plans to begin clinical trials in 2009 and commercial to launch in the United States by 2012. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members